Verona Pharma Plc, a rising star in respiratory therapeutics, is set to present a comprehensive suite of findings from its successful Phase 3 ENHANCE studies involving Ohtuvayre, a novel treatment for Chronic Obstructive Pulmonary Disease (COPD). The company s impactful research will be highlighted through one oral presentation and three posters at the prestigious European Respiratory Society (ERS) International Congress 2024. This event marks a significant opportunity for Verona Pharma to share pivotal data with the global respiratory community.The ENHANCE studies, designed to scrutinize the efficacy and safety profile of Ohtuvayre, have previously demonstrated promising outcomes. These findings have the po...
Verona Pharma s Ohtuvayre (ensifentrine) Receives FDA Approval for COPD Maintenance Treatment, Boosting Revenue ProspectsVerona Pharma Plc, a renowned biopharmaceutical company, has recently achieved a significant milestone with the US Food and Drug Administration (FDA) granting approval for its novel medication, Ohtuvayre (ensifentrine). This groundbreaking drug is now cleared for use in the maintenance treatment of chronic obstructive pulmonary disease (COPD) among adult patients. Verona Pharma s acquisition of this approval represents a major triumph for the company and offers a new ray of hope for individuals suffering from this debilitating condition.COPD is a progressive lung disease characterized by r...
Sources:
Verona Pharma Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Verona Pharma Plc’s corporate clients.
For your research, we’ve provided 9 tables on Verona Pharma Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0 %